HealthQuill Food and Drug Administration
The US Food and Drug Administration has approved Apellis Pharmaceuticals, Inc.’s medicine for treating two rare and serious kidney diseases.
Drugs Health Pharma

FDA approves Apellis’ therapy to treat two serious, rare kidney diseases

HQ Team July 30, 2025: The US Food and Drug Administration has approved Apellis Pharmaceuticals, Inc.’s medicine for treating two rare and serious.

Read More
The US Food and Drug Administration cleared PTC Therapeutics’ sepiapterin for treating children and adults with a rare genetic condition where the body cannot break down a part of protein called phenylalanine, which comes from foods like meat, eggs, and milk.
Drugs Health Pharma

US regulator clears PTC’s medicine to treat a rare genetic metabolic disease 

HQ Team July 29, 2025: The US Food and Drug Administration cleared PTC Therapeutics’ sepiapterin for treating children and adults with a rare.

Read More
AbbVie Inc. and IGI Therapeutics SA have signed a $2 billion licensing agreement that gives AbbVie access to an antibody being tested for certain types of cancers and autoimmune conditions.
Drugs Health Pharma

AbbVie inks $2 billion deal with IGI, bags antibody to fight cancer 

HQ Team July 10, 2025: AbbVie Inc. and IGI Therapeutics SA have signed a $2 billion licensing agreement that gives AbbVie access to.

Read More
The US drug regulator has approved changes in the prescription of Eli Lilly’s drug Kisunla for treating adults with early Alzheimer’s disease, including those with mild memory problems or mild dementia.
Drugs Health Pharma

FDA permits slow dosing of Eli Lilly’s Alzheimer’s drug Kisunla

HQ Team July 9, 2025: The US drug regulator has approved changes in the prescription of Eli Lilly’s drug Kisunla for treating adults.

Read More
Merck & Co. will acquire UK-based Verona Pharma Plc for about $10 billion to gain access to a respiratory drug approved by the US regulator, according to a statement from Merck.
Drugs Health Pharma

Merck to acquire Verona Pharma for $10 billion to net respiratory drug 

HQ Team July 9, 2025: Merck & Co. will acquire UK-based Verona Pharma Plc for about $10 billion and gain access to a.

Read More
Regeneron Pharmaceuticals, Inc.’s drug for a type of blood cancer in patients who have received four treatments before, and the disease has recurred, has received the US regulator’s green light.
Drugs Health Pharma

Regenron’s drug to treat a type of blood cancer gets US regulator’s nod

HQ Team June 3, 2025: Regeneron Pharmaceuticals, Inc.’s drug for a type of blood cancer in patients who have received four treatments before,.

Read More
Gilead Sciences, Inc.’s twice-yearly injectable drug for the prevention of HIV in adults and adolescents got approval from the US regulator.
Uncategorized

Gilead’s Yeztugo drug for HIV prevention in adults gets FDA nod

HQ Team June 19, 2025: Gilead Sciences, Inc.’s twice-yearly injectable drug for the prevention of HIV in adults and adolescents got approval from.

Read More
The US drug regulator has announced an immediate review of new clinical trials that involve sending American citizens’ living cells to China and other “hostile countries” for the fear of genetic data misuse.
Drugs Health Pharma

US to review trials to stop genetic data misuse by China, ‘hostile’ nations

HQ Team June 19, 2025: The US drug regulator has announced an immediate review of new clinical trials that involve sending American citizens’.

Read More
The US drug regulator approved Moderna Inc.’s respiratory syncytial virus vaccine for expanded use among people aged between 18 and 59 years.
Drugs Health Pharma

US regulator gives nod for Moderna’s expanded use of mRNA vaccine

HQ Team June 13, 2025: The US drug regulator approved Moderna Inc.’s respiratory syncytial virus vaccine for expanded use among people aged between.

Read More
Rein Therapeutics, Inc. has paused its enrollment and patient dosing at its US clinical trial sites testing a lung disease drug, after the regulator placed the experiment on clinical hold. 
Drugs Health Pharma

Rein Therapeutics’ trial drug for lung disease disorder put on clinical hold

HQ Team July 13, 2025: Rein Therapeutics, Inc., has paused its enrollment and patient dosing at its US clinical trial sites testing a.

Read More